Technology

NovaBiotics has looked to nature as the template for engineering a totally novel class of antimicrobial peptide therapies and believes its patented, proprietary technology has the potential to meet the need for safer, more effective antimicrobials and address the various and well described shortcomings of conventional anti-infective therapies. Importantly, the mode of action of NovaBiotics' compounds is such that they kill rather than merely inhibit pathogens and the likelihood of acquired or transmitted pathogen resistance developing in micro-organisms which have been exposed to the peptides is highly unlikely, if not impossible.

NovaBiotics has focused on peptides because in nature they form the cornerstone of the body's first line of defence against the spectrum of potentially harmful micro-organisms (bacteria, fungi, viruses, protozoa) with which we come into contact daily. NovaBiotics has capitalised on the benefical microbicidal properties of these natural infection-fighting agents and has designed third generation peptides that can be applied for the treatment and even prevention of a range of fungal and bacterial infections.

For more on the background behind NovaBiotics' technology click here.

Over-use of conventional antimicrobials, pathogen resistance and a spectrum of emerging organisms leaves the application and success of current antifungal and antibacterial therapies ever more limited. Global healthcare is facing an unprecedented crisis with a massive current and predicted future unmet clinical need for effective, safe and resistance-free therapies to combat bacterial, fungal, viral and other infectious diseases and conditions. Chemistry-led approaches have failed to solve this problem and so NovaBiotics has employed a very different approach; informed or rational drug design based approach versus high-risk screening.

Registered in Scotland No. SC272344. Registered Address: NovaBiotics Ltd, Cruickshank Building, Craibstone, Aberdeen, AB21 9TR, UK

Investors in People